Merck KGaA (WBO:MRCK) Cyclically Adjusted Revenue per Share: €49.21 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:MRCK Merck KGaA WBO:MRCK
79 GF Score
Price €139.75
GF Value €140.86
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Merck KGaA Cyclically Adjusted Revenue per Share?

Merck KGaA WBO:MRCK +1.60% 79 Cyclically Adjusted Revenue per Share is €49.21 as of Mar. 2026. GuruFocus rates WBO:MRCK with a GF Score™ of 79/100 and a GF Value™ of €140.86 (Fairly Valued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Merck KGaA's adjusted revenue per share for the three months ended in Mar. 2026 was €11.842. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €49.21 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Merck KGaA's average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Merck KGaA was 10.70% per year. The lowest was 5.40% per year. And the median was 8.40% per year.

As of today (2026-07-24), Merck KGaA's current stock price is €139.75. Merck KGaA's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €49.21. Merck KGaA's Cyclically Adjusted PS Ratio of today is 2.84.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Merck KGaA was 6.46. The lowest was 2.15. And the median was 3.46.


Merck KGaA  (WBO:MRCK) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Merck KGaA's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=139.75/49.21
=2.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Merck KGaA was 6.46. The lowest was 2.15. And the median was 3.46.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Merck KGaA Cyclically Adjusted Revenue per Share Related Terms


Merck KGaA Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Merck KGaA's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA Cyclically Adjusted Revenue per Share Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.84 40.80 43.40 46.22 48.18

Merck KGaA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.17 47.71 48.07 48.18 49.21

WBO:MRCK vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Merck KGaA's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck KGaA Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck KGaA's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Merck KGaA's Cyclically Adjusted PS Ratio falls into.


WBO:MRCK
79GF Score
Merck KGaA WBO:MRCK
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck KGaA Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Merck KGaA's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=11.842/131.2583*131.2583
=11.842

Current CPI (Mar. 2026) = 131.2583.

Merck KGaA Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 8.781 100.717 11.444
201609 8.556 101.017 11.117
201612 8.823 101.217 11.442
201703 8.859 101.417 11.466
201706 8.500 102.117 10.926
201709 8.083 102.717 10.329
201712 8.393 102.617 10.736
201803 7.974 102.917 10.170
201806 8.571 104.017 10.816
201809 8.601 104.718 10.781
201812 8.996 104.217 11.330
201903 8.523 104.217 10.734
201906 9.133 105.718 11.339
201909 9.337 106.018 11.560
201912 10.007 105.818 12.413
202003 10.062 105.718 12.493
202006 9.474 106.618 11.664
202009 10.220 105.818 12.677
202012 10.552 105.518 13.126
202103 10.663 107.518 13.017
202106 11.201 108.486 13.552
202109 11.436 109.435 13.717
202112 12.004 110.384 14.274
202203 11.932 113.968 13.742
202206 12.807 115.760 14.522
202209 13.336 118.818 14.732
202212 13.040 119.345 14.342
202303 12.169 122.402 13.049
202306 12.195 123.140 12.999
202309 11.900 124.195 12.577
202312 12.000 123.773 12.726
202403 11.804 125.038 12.391
202406 12.310 125.882 12.836
202409 12.107 126.198 12.592
202412 12.485 127.041 12.899
202503 12.140 127.779 12.471
202506 12.087 128.412 12.355
202509 12.204 129.255 12.393
202512 12.106 129.361 12.284
202603 11.842 131.258 11.842

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €49.21 mean?
Merck KGaA (WBO:MRCK) has a Cyclically Adjusted Revenue per Share of €49.21 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Merck KGaA and its competitors.
Is Merck KGaA's Cyclically Adjusted Revenue per Share too high?
Merck KGaA's current Cyclically Adjusted Revenue per Share is €49.21. Overall, Merck KGaA has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Merck KGaA's Cyclically Adjusted Revenue per Share of €49.21 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Merck KGaA and its competitors. Merck KGaA's current Cyclically Adjusted Revenue per Share is €49.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Based on GuruFocus' analysis, Merck KGaA (WBO:MRCK) is currently considered Fairly Valued. The stock's GF Value™ is €140.86, compared to a current price of €139.75 — trading 0.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €49.21. Merck KGaA's overall GF Score™ is 79/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Merck KGaA (WBO:MRCK), the current Cyclically Adjusted Revenue per Share is €49.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (WBO:MRCK) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be undervalued. The current stock price of €139.75 is trading 0.8% below its estimated GF Value™ of €140.86. GuruFocus considers Merck KGaA to be Fairly Valued.

Key valuation signals for WBO:MRCK:

  • Cyclically Adjusted Revenue per Share: €49.21
  • GF Value™: €140.86 vs. price of €139.75 (0.8% below fair value)
  • GF Score™: 79/100 with 10 warning signs

No single metric tells the full story. See the WBO:MRCK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
79GF Score

Get the complete analysis for WBO:MRCK

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€139.75
Price
€140.86
GF Value